<?xml version='1.0' encoding='UTF-8'?>
<extracted-tables-set><pmcid/><all-ids><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" pub-id-type="pmcid">PMC7025138</article-id><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" pub-id-type="pmcid-ver">PMC7025138.1</article-id><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" pub-id-type="pmcaid">7025138</article-id><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" pub-id-type="pmcaiid">7025138</article-id><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" pub-id-type="pmid">32062565</article-id><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" pub-id-type="doi">10.1016/j.nicl.2020.102203</article-id><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" pub-id-type="publisher-id">S2213-1582(20)30040-1</article-id><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" pub-id-type="publisher-id">102203</article-id></all-ids><extracted-table><table-id>tbl0001</table-id><table-label>Table 1</table-label><table-caption>Demographic and clinical characteristics of the ADNI participants</table-caption><table-wrap-foot/><original-table><table-wrap xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" position="float" id="tbl0001" orientation="portrait"><label>Table 1</label><caption><p>Demographic and clinical characteristics of the ADNI participants</p></caption><alt-text id="alt0007">Table 1</alt-text><table frame="hsides" rules="groups"><thead><tr><th valign="top" colspan="1" rowspan="1"/><th valign="top" colspan="1" rowspan="1">CN</th><th valign="top" colspan="1" rowspan="1">SMC</th><th valign="top" colspan="1" rowspan="1">EMCI</th><th valign="top" colspan="1" rowspan="1">LMCI</th><th valign="top" colspan="1" rowspan="1">AD</th></tr></thead><tbody><tr><td valign="top" colspan="1" rowspan="1">N</td><td valign="top" colspan="1" rowspan="1">57</td><td valign="top" colspan="1" rowspan="1">33</td><td valign="top" colspan="1" rowspan="1">76</td><td valign="top" colspan="1" rowspan="1">27</td><td valign="top" colspan="1" rowspan="1">76</td></tr><tr><td valign="top" colspan="1" rowspan="1">Age <bold>(SD)</bold></td><td valign="top" colspan="1" rowspan="1">75.91 (6.765)</td><td valign="top" colspan="1" rowspan="1">75.24 (5.432)</td><td valign="top" colspan="1" rowspan="1">75.58 (8.211)</td><td valign="top" colspan="1" rowspan="1">76 (6.884)</td><td valign="top" colspan="1" rowspan="1">76.43 (7.643)</td></tr><tr><td valign="top" colspan="1" rowspan="1">Gender (M/F)</td><td valign="top" colspan="1" rowspan="1">25/32</td><td valign="top" colspan="1" rowspan="1">12/21</td><td valign="top" colspan="1" rowspan="1">44/32</td><td valign="top" colspan="1" rowspan="1">18/9</td><td valign="top" colspan="1" rowspan="1">49/27</td></tr><tr><td valign="top" colspan="1" rowspan="1">APOE (ε4−/ε4+)</td><td valign="top" colspan="1" rowspan="1">37/19</td><td valign="top" colspan="1" rowspan="1">21/12</td><td valign="top" colspan="1" rowspan="1">45/29</td><td valign="top" colspan="1" rowspan="1">10/16</td><td valign="top" colspan="1" rowspan="1">22/53</td></tr></tbody></table></table-wrap></original-table><transformed-table>Table 1<div xmlns="http://www.w3.org/1999/xhtml" class="caption">Demographic and clinical characteristics of the ADNI participants</div>Table 1<div xmlns="http://www.w3.org/1999/xhtml" class="table"><table frame="hsides" rules="groups"><thead><tr><th valign="top"/><th valign="top">CN</th><th valign="top">SMC</th><th valign="top">EMCI</th><th valign="top">LMCI</th><th valign="top">AD</th></tr></thead><tbody><tr><td valign="top">N</td><td valign="top">57</td><td valign="top">33</td><td valign="top">76</td><td valign="top">27</td><td valign="top">76</td></tr><tr><td valign="top">Age (SD)</td><td valign="top">75.91 (6.765)</td><td valign="top">75.24 (5.432)</td><td valign="top">75.58 (8.211)</td><td valign="top">76 (6.884)</td><td valign="top">76.43 (7.643)</td></tr><tr><td valign="top">Gender (M/F)</td><td valign="top">25/32</td><td valign="top">12/21</td><td valign="top">44/32</td><td valign="top">18/9</td><td valign="top">49/27</td></tr><tr><td valign="top">APOE (ε4−/ε4+)</td><td valign="top">37/19</td><td valign="top">21/12</td><td valign="top">45/29</td><td valign="top">10/16</td><td valign="top">22/53</td></tr></tbody></table></div></transformed-table></extracted-table><extracted-table><table-id>tbl0002</table-id><table-label>Table 2</table-label><table-caption>The number of participants considered for the imaging-clinical/cognition correlation analyses across the five disease categories.</table-caption><table-wrap-foot/><original-table><table-wrap xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" position="float" id="tbl0002" orientation="portrait"><label>Table 2</label><caption><p>The number of participants considered for the imaging-clinical/cognition correlation analyses across the five disease categories.</p></caption><alt-text id="alt0008">Table 2</alt-text><table frame="hsides" rules="groups"><thead><tr><th valign="top" colspan="1" rowspan="1">Phenotypes</th><th valign="top" colspan="1" rowspan="1">CN</th><th valign="top" colspan="1" rowspan="1">SMC</th><th valign="top" colspan="1" rowspan="1">EMCI</th><th valign="top" colspan="1" rowspan="1">LMCI</th><th valign="top" colspan="1" rowspan="1">AD</th></tr></thead><tbody><tr><td valign="top" colspan="1" rowspan="1">Clinical</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1"><bold>ADAS13 (N=254)</bold></td><td valign="top" colspan="1" rowspan="1">57</td><td valign="top" colspan="1" rowspan="1">31</td><td valign="top" colspan="1" rowspan="1">72</td><td valign="top" colspan="1" rowspan="1">25</td><td valign="top" colspan="1" rowspan="1">69</td></tr><tr><td valign="top" colspan="1" rowspan="1"><bold>MMSE (N=255)</bold></td><td valign="top" colspan="1" rowspan="1">57</td><td valign="top" colspan="1" rowspan="1">31</td><td valign="top" colspan="1" rowspan="1">73</td><td valign="top" colspan="1" rowspan="1">25</td><td valign="top" colspan="1" rowspan="1">69</td></tr><tr><td valign="top" colspan="1" rowspan="1"><bold>MOCA (N=248)</bold></td><td valign="top" colspan="1" rowspan="1">57</td><td valign="top" colspan="1" rowspan="1">31</td><td valign="top" colspan="1" rowspan="1">71</td><td valign="top" colspan="1" rowspan="1">25</td><td valign="top" colspan="1" rowspan="1">64</td></tr><tr><td valign="top" colspan="1" rowspan="1"><bold>RAVLT_immediate (N=251)</bold></td><td valign="top" colspan="1" rowspan="1">56</td><td valign="top" colspan="1" rowspan="1">31</td><td valign="top" colspan="1" rowspan="1">73</td><td valign="top" colspan="1" rowspan="1">25</td><td valign="top" colspan="1" rowspan="1">66</td></tr><tr><td valign="top" colspan="1" rowspan="1"><bold>RAVLT_learning (N=251)</bold></td><td valign="top" colspan="1" rowspan="1">56</td><td valign="top" colspan="1" rowspan="1">31</td><td valign="top" colspan="1" rowspan="1">73</td><td valign="top" colspan="1" rowspan="1">25</td><td valign="top" colspan="1" rowspan="1">66</td></tr><tr><td valign="top" colspan="1" rowspan="1"><bold>RAVLT_forgetting (N=250)</bold></td><td valign="top" colspan="1" rowspan="1">56</td><td valign="top" colspan="1" rowspan="1">31</td><td valign="top" colspan="1" rowspan="1">73</td><td valign="top" colspan="1" rowspan="1">25</td><td valign="top" colspan="1" rowspan="1">65</td></tr><tr><td valign="top" colspan="1" rowspan="1"><bold>FAQ (N=251)</bold></td><td valign="top" colspan="1" rowspan="1">56</td><td valign="top" colspan="1" rowspan="1">31</td><td valign="top" colspan="1" rowspan="1">69</td><td valign="top" colspan="1" rowspan="1">25</td><td valign="top" colspan="1" rowspan="1">70</td></tr><tr><td valign="top" colspan="1" rowspan="1"><bold>EcogPtTotal (N=249)</bold></td><td valign="top" colspan="1" rowspan="1">57</td><td valign="top" colspan="1" rowspan="1">31</td><td valign="top" colspan="1" rowspan="1">72</td><td valign="top" colspan="1" rowspan="1">25</td><td valign="top" colspan="1" rowspan="1">64</td></tr><tr><td valign="top" colspan="1" rowspan="1"><bold>EcogSPTotal (N=246)</bold></td><td valign="top" colspan="1" rowspan="1">56</td><td valign="top" colspan="1" rowspan="1">30</td><td valign="top" colspan="1" rowspan="1">65</td><td valign="top" colspan="1" rowspan="1">25</td><td valign="top" colspan="1" rowspan="1">70</td></tr><tr><td valign="top" colspan="1" rowspan="1"><bold>CDRSB (251)</bold></td><td valign="top" colspan="1" rowspan="1">56</td><td valign="top" colspan="1" rowspan="1">30</td><td valign="top" colspan="1" rowspan="1">70</td><td valign="top" colspan="1" rowspan="1">25</td><td valign="top" colspan="1" rowspan="1">70</td></tr><tr><td valign="top" colspan="1" rowspan="1">AD-pathology related</td><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/><td valign="top" colspan="1" rowspan="1"/></tr><tr><td valign="top" colspan="1" rowspan="1"><bold>CSF_ABETA (N=50)</bold></td><td valign="top" colspan="1" rowspan="1">12</td><td valign="top" colspan="1" rowspan="1">12</td><td valign="top" colspan="1" rowspan="1">6</td><td valign="top" colspan="1" rowspan="1">4</td><td valign="top" colspan="1" rowspan="1">16</td></tr><tr><td valign="top" colspan="1" rowspan="1"><bold>CSF_TAU (N=62)</bold></td><td valign="top" colspan="1" rowspan="1">14</td><td valign="top" colspan="1" rowspan="1">17</td><td valign="top" colspan="1" rowspan="1">10</td><td valign="top" colspan="1" rowspan="1">5</td><td valign="top" colspan="1" rowspan="1">16</td></tr><tr><td valign="top" colspan="1" rowspan="1"><bold>CSF_PTAU (N=62)</bold></td><td valign="top" colspan="1" rowspan="1">14</td><td valign="top" colspan="1" rowspan="1">17</td><td valign="top" colspan="1" rowspan="1">10</td><td valign="top" colspan="1" rowspan="1">5</td><td valign="top" colspan="1" rowspan="1">16</td></tr><tr><td valign="top" colspan="1" rowspan="1"><bold><sup>[18F]</sup>Florbetapir PET (AV45) (N=134)</bold></td><td valign="top" colspan="1" rowspan="1">36</td><td valign="top" colspan="1" rowspan="1">25</td><td valign="top" colspan="1" rowspan="1">30</td><td valign="top" colspan="1" rowspan="1">12</td><td valign="top" colspan="1" rowspan="1">31</td></tr><tr><td valign="top" colspan="1" rowspan="1"><bold>FDG_PET (N=44)</bold></td><td valign="top" colspan="1" rowspan="1">13</td><td valign="top" colspan="1" rowspan="1">4</td><td valign="top" colspan="1" rowspan="1">10</td><td valign="top" colspan="1" rowspan="1">3</td><td valign="top" colspan="1" rowspan="1">14</td></tr></tbody></table></table-wrap></original-table><transformed-table>Table 2<div xmlns="http://www.w3.org/1999/xhtml" class="caption">The number of participants considered for the imaging-clinical/cognition correlation analyses across the five disease categories.</div>Table 2<div xmlns="http://www.w3.org/1999/xhtml" class="table"><table frame="hsides" rules="groups"><thead><tr><th valign="top">Phenotypes</th><th valign="top">CN</th><th valign="top">SMC</th><th valign="top">EMCI</th><th valign="top">LMCI</th><th valign="top">AD</th></tr></thead><tbody><tr><td valign="top">Clinical</td><td valign="top"/><td valign="top"/><td valign="top"/><td valign="top"/><td valign="top"/></tr><tr><td valign="top">ADAS13 (N=254)</td><td valign="top">57</td><td valign="top">31</td><td valign="top">72</td><td valign="top">25</td><td valign="top">69</td></tr><tr><td valign="top">MMSE (N=255)</td><td valign="top">57</td><td valign="top">31</td><td valign="top">73</td><td valign="top">25</td><td valign="top">69</td></tr><tr><td valign="top">MOCA (N=248)</td><td valign="top">57</td><td valign="top">31</td><td valign="top">71</td><td valign="top">25</td><td valign="top">64</td></tr><tr><td valign="top">RAVLT_immediate (N=251)</td><td valign="top">56</td><td valign="top">31</td><td valign="top">73</td><td valign="top">25</td><td valign="top">66</td></tr><tr><td valign="top">RAVLT_learning (N=251)</td><td valign="top">56</td><td valign="top">31</td><td valign="top">73</td><td valign="top">25</td><td valign="top">66</td></tr><tr><td valign="top">RAVLT_forgetting (N=250)</td><td valign="top">56</td><td valign="top">31</td><td valign="top">73</td><td valign="top">25</td><td valign="top">65</td></tr><tr><td valign="top">FAQ (N=251)</td><td valign="top">56</td><td valign="top">31</td><td valign="top">69</td><td valign="top">25</td><td valign="top">70</td></tr><tr><td valign="top">EcogPtTotal (N=249)</td><td valign="top">57</td><td valign="top">31</td><td valign="top">72</td><td valign="top">25</td><td valign="top">64</td></tr><tr><td valign="top">EcogSPTotal (N=246)</td><td valign="top">56</td><td valign="top">30</td><td valign="top">65</td><td valign="top">25</td><td valign="top">70</td></tr><tr><td valign="top">CDRSB (251)</td><td valign="top">56</td><td valign="top">30</td><td valign="top">70</td><td valign="top">25</td><td valign="top">70</td></tr><tr><td valign="top">AD-pathology related</td><td valign="top"/><td valign="top"/><td valign="top"/><td valign="top"/><td valign="top"/></tr><tr><td valign="top">CSF_ABETA (N=50)</td><td valign="top">12</td><td valign="top">12</td><td valign="top">6</td><td valign="top">4</td><td valign="top">16</td></tr><tr><td valign="top">CSF_TAU (N=62)</td><td valign="top">14</td><td valign="top">17</td><td valign="top">10</td><td valign="top">5</td><td valign="top">16</td></tr><tr><td valign="top">CSF_PTAU (N=62)</td><td valign="top">14</td><td valign="top">17</td><td valign="top">10</td><td valign="top">5</td><td valign="top">16</td></tr><tr><td valign="top">[18F]Florbetapir PET (AV45) (N=134)</td><td valign="top">36</td><td valign="top">25</td><td valign="top">30</td><td valign="top">12</td><td valign="top">31</td></tr><tr><td valign="top">FDG_PET (N=44)</td><td valign="top">13</td><td valign="top">4</td><td valign="top">10</td><td valign="top">3</td><td valign="top">14</td></tr></tbody></table></div></transformed-table></extracted-table><extracted-table><table-id>tbl0003</table-id><table-label>Table 2a</table-label><table-caption>Known pathways enriched in the gene modules significantly correlated with DTI-features in specific brain regions. The column Corrected p-value shows corrected p values for the Spearman's rank correlation between the indicated DTI feature and gene expression module.</table-caption><table-wrap-foot/><original-table><table-wrap xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" position="float" id="tbl0003" orientation="portrait"><label>Table 2a</label><caption><p>Known pathways enriched in the gene modules significantly correlated with DTI-features in specific brain regions. The column Corrected <italic toggle="yes">p</italic>-value shows corrected <italic toggle="yes">p</italic> values for the Spearman's rank correlation between the indicated DTI feature and gene expression module.</p></caption><alt-text id="alt0009">Table 2a</alt-text><table frame="hsides" rules="groups"><thead><tr><th valign="top" colspan="1" rowspan="1">Region</th><th valign="top" colspan="1" rowspan="1">DTI Feature</th><th valign="top" colspan="1" rowspan="1">Coexpression Module</th><th valign="top" colspan="1" rowspan="1">Enriched Pathways</th><th valign="top" colspan="1" rowspan="1">Corrected p-value</th></tr></thead><tbody><tr><td valign="top" colspan="1" rowspan="1">Superior occipital gyrus right</td><td valign="top" colspan="1" rowspan="1">FA</td><td valign="top" colspan="1" rowspan="1">M30</td><td valign="top" colspan="1" rowspan="1">immune response, response to cytokine, cytokine-mediated signaling pathway, innate immune response, regulation of immune system process</td><td valign="top" colspan="1" rowspan="1">1.34 × 10<sup>−2</sup></td></tr><tr><td valign="top" colspan="1" rowspan="1">Supramarginal gyrus left</td><td valign="top" colspan="1" rowspan="1">PLA</td><td valign="top" colspan="1" rowspan="1">M30</td><td valign="top" colspan="1" rowspan="1">immune response, response to cytokine, cytokine-mediated signaling pathway, innate immune response, regulation of immune system process</td><td valign="top" colspan="1" rowspan="1">1.62 × 10<sup>−2</sup></td></tr><tr><td valign="top" colspan="1" rowspan="1">Supramarginal gyrus right</td><td valign="top" colspan="1" rowspan="1">PLA</td><td valign="top" colspan="1" rowspan="1">M30</td><td valign="top" colspan="1" rowspan="1">immune response, response to cytokine, cytokine-mediated signaling pathway, innate immune response, regulation of immune system process</td><td valign="top" colspan="1" rowspan="1">2.16 × 10<sup>−2</sup></td></tr><tr><td valign="top" colspan="1" rowspan="1">Supramarginal gyrus left</td><td valign="top" colspan="1" rowspan="1">LIN</td><td valign="top" colspan="1" rowspan="1">M30</td><td valign="top" colspan="1" rowspan="1">immune response, response to cytokine, cytokine-mediated signaling pathway, innate immune response, regulation of immune system process</td><td valign="top" colspan="1" rowspan="1">2.70 × 10<sup>−2</sup></td></tr><tr><td valign="top" colspan="1" rowspan="1">Postcentral gyrus right</td><td valign="top" colspan="1" rowspan="1">PLA</td><td valign="top" colspan="1" rowspan="1">M30</td><td valign="top" colspan="1" rowspan="1">immune response, response to cytokine, cytokine-mediated signaling pathway, innate immune response, regulation of immune system process</td><td valign="top" colspan="1" rowspan="1">2.97 × 10<sup>−2</sup></td></tr><tr><td valign="top" colspan="1" rowspan="1">Supramarginal gyrus right</td><td valign="top" colspan="1" rowspan="1">MD</td><td valign="top" colspan="1" rowspan="1">M30</td><td valign="top" colspan="1" rowspan="1">immune response, response to cytokine, cytokine-mediated signaling pathway, innate immune response, regulation of immune system process</td><td valign="top" colspan="1" rowspan="1">3.24 × 10<sup>−2</sup></td></tr><tr><td valign="top" colspan="1" rowspan="1">Supramarginal gyrus right</td><td valign="top" colspan="1" rowspan="1">RD</td><td valign="top" colspan="1" rowspan="1">M30</td><td valign="top" colspan="1" rowspan="1">immune response, response to cytokine, cytokine-mediated signaling pathway, innate immune response, regulation of immune system process</td><td valign="top" colspan="1" rowspan="1">3.38 × 10<sup>−2</sup></td></tr><tr><td valign="top" colspan="1" rowspan="1">Corticospinal tract left</td><td valign="top" colspan="1" rowspan="1">ODI</td><td valign="top" colspan="1" rowspan="1">M18</td><td valign="top" colspan="1" rowspan="1">Sensory perception, nervous system process and G-protein coupled receptor signaling pathway</td><td valign="top" colspan="1" rowspan="1">3.92 × 10<sup>−2</sup></td></tr><tr><td valign="top" colspan="1" rowspan="1">Inferior fronto occipital fasciculus right</td><td valign="top" colspan="1" rowspan="1">ODI</td><td valign="top" colspan="1" rowspan="1">M145</td><td valign="top" colspan="1" rowspan="1">Cell-cell adhesion, IRE1-mediated unfolded protein response, RNA interference and posttranscriptional regulation of gene expression</td><td valign="top" colspan="1" rowspan="1">4.32 × 10<sup>−2</sup></td></tr><tr><td valign="top" colspan="1" rowspan="1">Supramarginal gyrus right</td><td valign="top" colspan="1" rowspan="1">L1</td><td valign="top" colspan="1" rowspan="1">M30</td><td valign="top" colspan="1" rowspan="1">immune response, response to cytokine, cytokine-mediated signaling pathway, innate immune response, regulation of immune system process</td><td valign="top" colspan="1" rowspan="1">4.32 × 10<sup>−2</sup></td></tr><tr><td valign="top" colspan="1" rowspan="1">Fusiform WM left</td><td valign="top" colspan="1" rowspan="1">MD</td><td valign="top" colspan="1" rowspan="1">M26</td><td valign="top" colspan="1" rowspan="1">immune response, response to cytokine, cytokine-mediated signaling pathway, innate immune response, regulation of immune system process</td><td valign="top" colspan="1" rowspan="1">4.46 × 10<sup>−2</sup></td></tr><tr><td valign="top" colspan="1" rowspan="1">Medulla right</td><td valign="top" colspan="1" rowspan="1">MOD</td><td valign="top" colspan="1" rowspan="1">M23</td><td valign="top" colspan="1" rowspan="1">cell surface receptor signaling pathway, neurotrophin TRK receptor signaling pathway, B cell activation, cell differentiation, regulation of response to stimulus and cellular developmental process</td><td valign="top" colspan="1" rowspan="1">8.51 × 10<sup>−3</sup></td></tr></tbody></table></table-wrap></original-table><transformed-table>Table 2a<div xmlns="http://www.w3.org/1999/xhtml" class="caption">Known pathways enriched in the gene modules significantly correlated with DTI-features in specific brain regions. The column Corrected p-value shows corrected p values for the Spearman's rank correlation between the indicated DTI feature and gene expression module.</div>Table 2a<div xmlns="http://www.w3.org/1999/xhtml" class="table"><table frame="hsides" rules="groups"><thead><tr><th valign="top">Region</th><th valign="top">DTI Feature</th><th valign="top">Coexpression Module</th><th valign="top">Enriched Pathways</th><th valign="top">Corrected p-value</th></tr></thead><tbody><tr><td valign="top">Superior occipital gyrus right</td><td valign="top">FA</td><td valign="top">M30</td><td valign="top">immune response, response to cytokine, cytokine-mediated signaling pathway, innate immune response, regulation of immune system process</td><td valign="top">1.34 × 10−2</td></tr><tr><td valign="top">Supramarginal gyrus left</td><td valign="top">PLA</td><td valign="top">M30</td><td valign="top">immune response, response to cytokine, cytokine-mediated signaling pathway, innate immune response, regulation of immune system process</td><td valign="top">1.62 × 10−2</td></tr><tr><td valign="top">Supramarginal gyrus right</td><td valign="top">PLA</td><td valign="top">M30</td><td valign="top">immune response, response to cytokine, cytokine-mediated signaling pathway, innate immune response, regulation of immune system process</td><td valign="top">2.16 × 10−2</td></tr><tr><td valign="top">Supramarginal gyrus left</td><td valign="top">LIN</td><td valign="top">M30</td><td valign="top">immune response, response to cytokine, cytokine-mediated signaling pathway, innate immune response, regulation of immune system process</td><td valign="top">2.70 × 10−2</td></tr><tr><td valign="top">Postcentral gyrus right</td><td valign="top">PLA</td><td valign="top">M30</td><td valign="top">immune response, response to cytokine, cytokine-mediated signaling pathway, innate immune response, regulation of immune system process</td><td valign="top">2.97 × 10−2</td></tr><tr><td valign="top">Supramarginal gyrus right</td><td valign="top">MD</td><td valign="top">M30</td><td valign="top">immune response, response to cytokine, cytokine-mediated signaling pathway, innate immune response, regulation of immune system process</td><td valign="top">3.24 × 10−2</td></tr><tr><td valign="top">Supramarginal gyrus right</td><td valign="top">RD</td><td valign="top">M30</td><td valign="top">immune response, response to cytokine, cytokine-mediated signaling pathway, innate immune response, regulation of immune system process</td><td valign="top">3.38 × 10−2</td></tr><tr><td valign="top">Corticospinal tract left</td><td valign="top">ODI</td><td valign="top">M18</td><td valign="top">Sensory perception, nervous system process and G-protein coupled receptor signaling pathway</td><td valign="top">3.92 × 10−2</td></tr><tr><td valign="top">Inferior fronto occipital fasciculus right</td><td valign="top">ODI</td><td valign="top">M145</td><td valign="top">Cell-cell adhesion, IRE1-mediated unfolded protein response, RNA interference and posttranscriptional regulation of gene expression</td><td valign="top">4.32 × 10−2</td></tr><tr><td valign="top">Supramarginal gyrus right</td><td valign="top">L1</td><td valign="top">M30</td><td valign="top">immune response, response to cytokine, cytokine-mediated signaling pathway, innate immune response, regulation of immune system process</td><td valign="top">4.32 × 10−2</td></tr><tr><td valign="top">Fusiform WM left</td><td valign="top">MD</td><td valign="top">M26</td><td valign="top">immune response, response to cytokine, cytokine-mediated signaling pathway, innate immune response, regulation of immune system process</td><td valign="top">4.46 × 10−2</td></tr><tr><td valign="top">Medulla right</td><td valign="top">MOD</td><td valign="top">M23</td><td valign="top">cell surface receptor signaling pathway, neurotrophin TRK receptor signaling pathway, B cell activation, cell differentiation, regulation of response to stimulus and cellular developmental process</td><td valign="top">8.51 × 10−3</td></tr></tbody></table></div></transformed-table></extracted-table><extracted-table><table-id>tbl0004</table-id><table-label>Table 3</table-label><table-caption>Set-based association for 23 IGAP loci and the FA feature using all the common variants (MAF ≥ 0.05) in the neighborhood of the identified risk gene corresponding to each AD risk locus. Empirical p-values were calculated using 20,000 permutations in PLINK.</table-caption><table-wrap-foot/><original-table><table-wrap xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" position="float" id="tbl0004" orientation="portrait"><label>Table 3</label><caption><p>Set-based association for 23 IGAP loci and the FA feature using all the common variants (MAF ≥ 0.05) in the neighborhood of the identified risk gene corresponding to each AD risk locus. Empirical <italic toggle="yes">p</italic>-values were calculated using 20,000 permutations in PLINK.</p></caption><alt-text id="alt0010">Table 3</alt-text><table frame="hsides" rules="groups"><thead><tr><th valign="top" colspan="1" rowspan="1">Gene</th><th valign="top" colspan="1" rowspan="1">Number of SNPs in gene</th><th valign="top" colspan="1" rowspan="1">Number of significant SNPs (<italic toggle="yes">p</italic> &lt; 0.05, <italic toggle="yes">r</italic><sup>2</sup> &lt; 0.5)</th><th valign="top" colspan="1" rowspan="1">Empirical gene-based p-value</th><th valign="top" colspan="1" rowspan="1">List of significant SNP</th></tr></thead><tbody><tr><td valign="top" colspan="1" rowspan="1"><italic toggle="yes">CELF1</italic></td><td valign="top" colspan="1" rowspan="1">346</td><td valign="top" colspan="1" rowspan="1">4</td><td valign="top" colspan="1" rowspan="1">8 × 10<sup>−4</sup></td><td valign="top" colspan="1" rowspan="1">rs7118178|rs7925299| rs2203712|rs71475924</td></tr><tr><td valign="top" colspan="1" rowspan="1"><italic toggle="yes">CLU</italic></td><td valign="top" colspan="1" rowspan="1">539</td><td valign="top" colspan="1" rowspan="1">3</td><td valign="top" colspan="1" rowspan="1">0.0117</td><td valign="top" colspan="1" rowspan="1">rs11135998|rs59953408| rs532754</td></tr><tr><td valign="top" colspan="1" rowspan="1"><italic toggle="yes">SORL1</italic></td><td valign="top" colspan="1" rowspan="1">540</td><td valign="top" colspan="1" rowspan="1">5</td><td valign="top" colspan="1" rowspan="1">0.01405</td><td valign="top" colspan="1" rowspan="1">rs664424|rs11600686| rs4372460|rs12276905| rs10790451</td></tr><tr><td valign="top" colspan="1" rowspan="1"><italic toggle="yes">PICALM</italic></td><td valign="top" colspan="1" rowspan="1">687</td><td valign="top" colspan="1" rowspan="1">13</td><td valign="top" colspan="1" rowspan="1">0.1529</td><td valign="top" colspan="1" rowspan="1">rs471470|rs67598967| rs6592271|rs11234568| rs598561|rs11607590| rs56302636|rs11234555| rs3862786|rs10792829| rs11234549|rs12277986| rs11825598</td></tr><tr><td valign="top" colspan="1" rowspan="1"><italic toggle="yes">FERMT2</italic></td><td valign="top" colspan="1" rowspan="1">486</td><td valign="top" colspan="1" rowspan="1">1</td><td valign="top" colspan="1" rowspan="1">0.2276</td><td valign="top" colspan="1" rowspan="1">rs62003479</td></tr><tr><td valign="top" colspan="1" rowspan="1"><italic toggle="yes">HLA-DRB5</italic></td><td valign="top" colspan="1" rowspan="1">373</td><td valign="top" colspan="1" rowspan="1">2</td><td valign="top" colspan="1" rowspan="1">0.2783</td><td valign="top" colspan="1" rowspan="1">rs9271176|rs680151</td></tr><tr><td valign="top" colspan="1" rowspan="1"><italic toggle="yes">SLC24A4</italic></td><td valign="top" colspan="1" rowspan="1">1134</td><td valign="top" colspan="1" rowspan="1">10</td><td valign="top" colspan="1" rowspan="1">0.2957</td><td valign="top" colspan="1" rowspan="1">rs79544202|rs12434183| rs9972287|rs34723497| rs1108161|rs55840245| rs4904955|rs12436499| rs66753927|rs55866218</td></tr><tr><td valign="top" colspan="1" rowspan="1"><italic toggle="yes">HLA-DRB1</italic></td><td valign="top" colspan="1" rowspan="1">399</td><td valign="top" colspan="1" rowspan="1">2</td><td valign="top" colspan="1" rowspan="1">0.3195</td><td valign="top" colspan="1" rowspan="1">rs9271176|rs680151</td></tr><tr><td valign="top" colspan="1" rowspan="1"><italic toggle="yes">EPHA1</italic></td><td valign="top" colspan="1" rowspan="1">450</td><td valign="top" colspan="1" rowspan="1">3</td><td valign="top" colspan="1" rowspan="1">0.3443</td><td valign="top" colspan="1" rowspan="1">rs73154208|rs55893042| rs7810606</td></tr><tr><td valign="top" colspan="1" rowspan="1"><italic toggle="yes">CASS4</italic></td><td valign="top" colspan="1" rowspan="1">494</td><td valign="top" colspan="1" rowspan="1">3</td><td valign="top" colspan="1" rowspan="1">0.3445</td><td valign="top" colspan="1" rowspan="1">rs6024817|rs6024937| rs11906849</td></tr><tr><td valign="top" colspan="1" rowspan="1"><italic toggle="yes">RIN3</italic></td><td valign="top" colspan="1" rowspan="1">1093</td><td valign="top" colspan="1" rowspan="1">5</td><td valign="top" colspan="1" rowspan="1">0.3584</td><td valign="top" colspan="1" rowspan="1">rs12434183|rs55977629|rs55840245|rs4904955| rs1242105</td></tr><tr><td valign="top" colspan="1" rowspan="1"><italic toggle="yes">CD33</italic></td><td valign="top" colspan="1" rowspan="1">320</td><td valign="top" colspan="1" rowspan="1">13</td><td valign="top" colspan="1" rowspan="1">0.3916</td><td valign="top" colspan="1" rowspan="1">rs10425414|rs273692| rs2134068|rs7253654| rs34564964|rs2411329| rs3887787|rs35982135| rs79254320|rs1710353| rs10409348|rs73055137| rs4802772</td></tr><tr><td valign="top" colspan="1" rowspan="1"><italic toggle="yes">INPP5D</italic></td><td valign="top" colspan="1" rowspan="1">577</td><td valign="top" colspan="1" rowspan="1">6</td><td valign="top" colspan="1" rowspan="1">0.4419</td><td valign="top" colspan="1" rowspan="1">rs72984219|rs7581670| rs3792106|rs59199559| rs62192899|rs62192926</td></tr><tr><td valign="top" colspan="1" rowspan="1"><italic toggle="yes">BIN1</italic></td><td valign="top" colspan="1" rowspan="1">908</td><td valign="top" colspan="1" rowspan="1">3</td><td valign="top" colspan="1" rowspan="1">0.4477</td><td valign="top" colspan="1" rowspan="1">rs6716819|rs6431230| rs13031473</td></tr><tr><td valign="top" colspan="1" rowspan="1"><italic toggle="yes">PTK2B</italic></td><td valign="top" colspan="1" rowspan="1">779</td><td valign="top" colspan="1" rowspan="1">13</td><td valign="top" colspan="1" rowspan="1">0.4514</td><td valign="top" colspan="1" rowspan="1">rs17375582|rs2565045| rs2322607|rs11780471| rs11994882|rs2565048| rs2241657|rs7000615| rs1367088|rs187228254| rs7013346|rs2271920| rs2741341</td></tr><tr><td valign="top" colspan="1" rowspan="1"><italic toggle="yes">ZCWPW1</italic></td><td valign="top" colspan="1" rowspan="1">234</td><td valign="top" colspan="1" rowspan="1">1</td><td valign="top" colspan="1" rowspan="1">0.5396</td><td valign="top" colspan="1" rowspan="1">rs118119933</td></tr><tr><td valign="top" colspan="1" rowspan="1"><italic toggle="yes">CR1</italic></td><td valign="top" colspan="1" rowspan="1">617</td><td valign="top" colspan="1" rowspan="1">3</td><td valign="top" colspan="1" rowspan="1">0.6456</td><td valign="top" colspan="1" rowspan="1">rs61821132|rs1570564| rs71515116</td></tr><tr><td valign="top" colspan="1" rowspan="1"><italic toggle="yes">NME8</italic></td><td valign="top" colspan="1" rowspan="1">750</td><td valign="top" colspan="1" rowspan="1">3</td><td valign="top" colspan="1" rowspan="1">0.6471</td><td valign="top" colspan="1" rowspan="1">rs1668347|rs2198050| rs1668357</td></tr><tr><td valign="top" colspan="1" rowspan="1"><italic toggle="yes">ABCA7</italic></td><td valign="top" colspan="1" rowspan="1">672</td><td valign="top" colspan="1" rowspan="1">7</td><td valign="top" colspan="1" rowspan="1">0.7435</td><td valign="top" colspan="1" rowspan="1">rs2240615|rs35500465| rs4147940|rs349310| rs8106918|rs4147912| rs7260506</td></tr><tr><td valign="top" colspan="1" rowspan="1"><italic toggle="yes">MEF2C</italic></td><td valign="top" colspan="1" rowspan="1">373</td><td valign="top" colspan="1" rowspan="1">3</td><td valign="top" colspan="1" rowspan="1">0.7944</td><td valign="top" colspan="1" rowspan="1">rs7728694|rs214134| rs75034114</td></tr><tr><td valign="top" colspan="1" rowspan="1"><italic toggle="yes">CD2AP</italic></td><td valign="top" colspan="1" rowspan="1">884</td><td valign="top" colspan="1" rowspan="1">1</td><td valign="top" colspan="1" rowspan="1">0.8546</td><td valign="top" colspan="1" rowspan="1">rs16876369</td></tr><tr><td valign="top" colspan="1" rowspan="1"><italic toggle="yes">DSG2</italic></td><td valign="top" colspan="1" rowspan="1">491</td><td valign="top" colspan="1" rowspan="1">1</td><td valign="top" colspan="1" rowspan="1">0.8602</td><td valign="top" colspan="1" rowspan="1">rs36032521</td></tr><tr><td valign="top" colspan="1" rowspan="1"><italic toggle="yes">MS4A6A</italic></td><td valign="top" colspan="1" rowspan="1">403</td><td valign="top" colspan="1" rowspan="1">0</td><td valign="top" colspan="1" rowspan="1">1</td><td valign="top" colspan="1" rowspan="1">NA</td></tr></tbody></table></table-wrap></original-table><transformed-table>Table 3<div xmlns="http://www.w3.org/1999/xhtml" class="caption">Set-based association for 23 IGAP loci and the FA feature using all the common variants (MAF ≥ 0.05) in the neighborhood of the identified risk gene corresponding to each AD risk locus. Empirical p-values were calculated using 20,000 permutations in PLINK.</div>Table 3<div xmlns="http://www.w3.org/1999/xhtml" class="table"><table frame="hsides" rules="groups"><thead><tr><th valign="top">Gene</th><th valign="top">Number of SNPs in gene</th><th valign="top">Number of significant SNPs (p &lt; 0.05, r2 &lt; 0.5)</th><th valign="top">Empirical gene-based p-value</th><th valign="top">List of significant SNP</th></tr></thead><tbody><tr><td valign="top">CELF1</td><td valign="top">346</td><td valign="top">4</td><td valign="top">8 × 10−4</td><td valign="top">rs7118178|rs7925299| rs2203712|rs71475924</td></tr><tr><td valign="top">CLU</td><td valign="top">539</td><td valign="top">3</td><td valign="top">0.0117</td><td valign="top">rs11135998|rs59953408| rs532754</td></tr><tr><td valign="top">SORL1</td><td valign="top">540</td><td valign="top">5</td><td valign="top">0.01405</td><td valign="top">rs664424|rs11600686| rs4372460|rs12276905| rs10790451</td></tr><tr><td valign="top">PICALM</td><td valign="top">687</td><td valign="top">13</td><td valign="top">0.1529</td><td valign="top">rs471470|rs67598967| rs6592271|rs11234568| rs598561|rs11607590| rs56302636|rs11234555| rs3862786|rs10792829| rs11234549|rs12277986| rs11825598</td></tr><tr><td valign="top">FERMT2</td><td valign="top">486</td><td valign="top">1</td><td valign="top">0.2276</td><td valign="top">rs62003479</td></tr><tr><td valign="top">HLA-DRB5</td><td valign="top">373</td><td valign="top">2</td><td valign="top">0.2783</td><td valign="top">rs9271176|rs680151</td></tr><tr><td valign="top">SLC24A4</td><td valign="top">1134</td><td valign="top">10</td><td valign="top">0.2957</td><td valign="top">rs79544202|rs12434183| rs9972287|rs34723497| rs1108161|rs55840245| rs4904955|rs12436499| rs66753927|rs55866218</td></tr><tr><td valign="top">HLA-DRB1</td><td valign="top">399</td><td valign="top">2</td><td valign="top">0.3195</td><td valign="top">rs9271176|rs680151</td></tr><tr><td valign="top">EPHA1</td><td valign="top">450</td><td valign="top">3</td><td valign="top">0.3443</td><td valign="top">rs73154208|rs55893042| rs7810606</td></tr><tr><td valign="top">CASS4</td><td valign="top">494</td><td valign="top">3</td><td valign="top">0.3445</td><td valign="top">rs6024817|rs6024937| rs11906849</td></tr><tr><td valign="top">RIN3</td><td valign="top">1093</td><td valign="top">5</td><td valign="top">0.3584</td><td valign="top">rs12434183|rs55977629|rs55840245|rs4904955| rs1242105</td></tr><tr><td valign="top">CD33</td><td valign="top">320</td><td valign="top">13</td><td valign="top">0.3916</td><td valign="top">rs10425414|rs273692| rs2134068|rs7253654| rs34564964|rs2411329| rs3887787|rs35982135| rs79254320|rs1710353| rs10409348|rs73055137| rs4802772</td></tr><tr><td valign="top">INPP5D</td><td valign="top">577</td><td valign="top">6</td><td valign="top">0.4419</td><td valign="top">rs72984219|rs7581670| rs3792106|rs59199559| rs62192899|rs62192926</td></tr><tr><td valign="top">BIN1</td><td valign="top">908</td><td valign="top">3</td><td valign="top">0.4477</td><td valign="top">rs6716819|rs6431230| rs13031473</td></tr><tr><td valign="top">PTK2B</td><td valign="top">779</td><td valign="top">13</td><td valign="top">0.4514</td><td valign="top">rs17375582|rs2565045| rs2322607|rs11780471| rs11994882|rs2565048| rs2241657|rs7000615| rs1367088|rs187228254| rs7013346|rs2271920| rs2741341</td></tr><tr><td valign="top">ZCWPW1</td><td valign="top">234</td><td valign="top">1</td><td valign="top">0.5396</td><td valign="top">rs118119933</td></tr><tr><td valign="top">CR1</td><td valign="top">617</td><td valign="top">3</td><td valign="top">0.6456</td><td valign="top">rs61821132|rs1570564| rs71515116</td></tr><tr><td valign="top">NME8</td><td valign="top">750</td><td valign="top">3</td><td valign="top">0.6471</td><td valign="top">rs1668347|rs2198050| rs1668357</td></tr><tr><td valign="top">ABCA7</td><td valign="top">672</td><td valign="top">7</td><td valign="top">0.7435</td><td valign="top">rs2240615|rs35500465| rs4147940|rs349310| rs8106918|rs4147912| rs7260506</td></tr><tr><td valign="top">MEF2C</td><td valign="top">373</td><td valign="top">3</td><td valign="top">0.7944</td><td valign="top">rs7728694|rs214134| rs75034114</td></tr><tr><td valign="top">CD2AP</td><td valign="top">884</td><td valign="top">1</td><td valign="top">0.8546</td><td valign="top">rs16876369</td></tr><tr><td valign="top">DSG2</td><td valign="top">491</td><td valign="top">1</td><td valign="top">0.8602</td><td valign="top">rs36032521</td></tr><tr><td valign="top">MS4A6A</td><td valign="top">403</td><td valign="top">0</td><td valign="top">1</td><td valign="top">NA</td></tr></tbody></table></div></transformed-table></extracted-table><extracted-table><table-id>tbl0005</table-id><table-label>Table 4</table-label><table-caption>Association of rs2203712 in CELF1 with neuroimaging phenotypes</table-caption><table-wrap-foot/><original-table><table-wrap xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" position="float" id="tbl0005" orientation="portrait"><label>Table 4</label><caption><p>Association of rs2203712 in <italic toggle="yes">CELF1</italic> with neuroimaging phenotypes</p></caption><alt-text id="alt0011">Table 4</alt-text><table frame="hsides" rules="groups"><thead><tr><th valign="top" colspan="1" rowspan="1">rs2203712</th><th valign="top" colspan="1" rowspan="1">p-value after adjusting for diagnosis</th><th valign="top" colspan="1" rowspan="1">p-value before adjusting for diagnosis</th></tr></thead><tbody><tr><td valign="top" colspan="1" rowspan="1">FA</td><td valign="top" colspan="1" rowspan="1">6.34 × 10<sup>−4</sup></td><td valign="top" colspan="1" rowspan="1">5.12 × 10<sup>−4</sup></td></tr><tr><td valign="top" colspan="1" rowspan="1">LIN</td><td valign="top" colspan="1" rowspan="1">1.4 × 10<sup>−3</sup></td><td valign="top" colspan="1" rowspan="1">1.17 × 10<sup>−3</sup></td></tr><tr><td valign="top" colspan="1" rowspan="1">ODI</td><td valign="top" colspan="1" rowspan="1">7 × 10<sup>−4</sup></td><td valign="top" colspan="1" rowspan="1">5.97 × 10<sup>−4</sup></td></tr></tbody></table></table-wrap></original-table><transformed-table>Table 4<div xmlns="http://www.w3.org/1999/xhtml" class="caption">Association of rs2203712 in CELF1 with neuroimaging phenotypes</div>Table 4<div xmlns="http://www.w3.org/1999/xhtml" class="table"><table frame="hsides" rules="groups"><thead><tr><th valign="top">rs2203712</th><th valign="top">p-value after adjusting for diagnosis</th><th valign="top">p-value before adjusting for diagnosis</th></tr></thead><tbody><tr><td valign="top">FA</td><td valign="top">6.34 × 10−4</td><td valign="top">5.12 × 10−4</td></tr><tr><td valign="top">LIN</td><td valign="top">1.4 × 10−3</td><td valign="top">1.17 × 10−3</td></tr><tr><td valign="top">ODI</td><td valign="top">7 × 10−4</td><td valign="top">5.97 × 10−4</td></tr></tbody></table></div></transformed-table></extracted-table></extracted-tables-set>